Hiep (Ben) Nguyen

Recognizing the signs and symptoms of chronic myeloid leukemia (CML) is essential for effective management. Early detection and understanding of key indicators play a crucial role in creating appropriate treatment strategies and improving outcomes for individuals with CML. Learn more about CML from the American Cancer Society at https://lnkd.in/eZfjAhe2 #CancerResearch #CancerResearchMonth #NCRM24

3

A new #CRISPR-based clinical trial for #SickleCell disease is enrolling at UCSF. This is the first therapy in the U.S. to apply non-viral CRISPR gene editing to directly correct the genetic mutation that causes the disease. Read more: https://ow.ly/Smry50UfZi1

32

Malte Lenders and colleagues conclude that the pharmacokinetic profile of pegunigalsidase alfa depends on the presence of neutralizing anti-AGAL antibodies, which result in reduced plasma half-life and peak enzyme activity after infusion. #pegunigalsidase #FabryDisease #Pharmacokinetics #openaccess https://lnkd.in/gt8CCkFS

3

https://lnkd.in/ex29Zi_h Synthesis of 2,4-Substituted Furans by the Treatment of β-Dialkylamino Chalcones with Dimethylsulfonium Methylide

5

Nonallosteric activation of posttranslational modification enzymes by active site-directed inhibitors. Read the article here: https://lnkd.in/gwPz7KWy

2

#analyticalchemistry news Unlocking Enzyme Potential: A Step Forward in Analytical Chemistry Recent advancements in #chemistry have unveiled a groundbreaking approach to enhancing the sensitivity and selectivity of redox enzyme activation and imaging. The study titled "Dual-Lock System for High Sensitivity and Selectivity in Redox Enzyme Activation and Imaging," published in Analytical Chemistry by So Jin Hong, Eunsol Jeon, Min Jung Kim, and Min Hee Lee, introduces an innovative "dual-lock" system that could revolutionise our understanding and application of enzyme-based analysis. Redox enzymes, integral to numerous biological processes, can provide vital insights into cellular environments. The dual-lock system acts as a precise switch, significantly improving the accuracy of enzyme assays by reducing background noise and enhancing signal clarity. This is achieved through a combination of molecular interactions that specifically target active enzymes, akin to unlocking a secured door. Such precision in enzyme activation and imaging opens new avenues in #biochemistry and #molecularbiology, with potential implications in medical diagnostics and environmental monitoring. By enabling more precise imaging, this technology could improve our ability to detect and understand diseases at their molecular level, offering hope for earlier diagnostics and more effective treatments. Imagine a world where medical professionals can trust enzyme-based tests for conditions ranging from diabetes to cancer. This study lays the groundwork for such possibilities, hinting at a future where #analyticalchemistry plays an even more crucial role in healthcare advancements. As we continue to push the boundaries of scientific exploration, contributions like this remind us of the pivotal role #chemistry plays in transforming theoretical concepts into practical solutions that could enhance our daily lives. #RedoxEnzymes #MedicalDiagnostics #biotechnology #scientificinnovation, If you want to know more about #analyticalchemistry news, follow me: https://lnkd.in/d29pbjb9

1

Positive results from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with Imfinzi in combination with neoadjuvant chemotherapy before radical cystectomy (surgery to remove the bladder) followed by Imfinzi as adjuvant monotherapy. These results will be presented today during a Presidential Symposium at the 2024 ESMO - European Society for Medical Oncology Congress in Barcelona, Spain (abstract #LBA5) and simultaneously published in The New England Journal of Medicine. Professor Tom Powles, MD, Director of Barts Cancer Institute (Queen Mary University of London), London, UK, and principal investigator in the NIAGARA trial, said: “Neoadjuvant chemotherapy with bladder removal has been the mainstay of treatment for patients with muscle-invasive bladder cancer for nearly twenty years; however, half of patients still go on to suffer a devastating recurrence. Adding durvalumab before and after surgery significantly reduced the chance of recurrence and extended survival, a significant advance with the potential to transform the standard of care for these patients who desperately need better outcomes.” Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “The NIAGARA data showed compelling improvements in both event-free survival and overall survival, with more than 80 per cent of patients treated with the Imfinzi perioperative regimen alive at two years. This is the first immunotherapy regimen to significantly extend overall survival in muscle-invasive bladder cancer, and it further validates our strategy to move cancer treatment as early as possible to maximise benefit for patients.” #oncology #bladdercancer #MIBC #clinicaltrials #durvalumab #Immunotherapy #Imfinzi #AstraZeneca #WhatScienceCanDo

225

What's new in our latest Pediatric & #Rare Liver Diseases News? 1️⃣ GLI is holding its Pediatric and Rare Liver Diseases Council Semi-Annual Meeting 2️⃣ UC Davis Health liver #transplant center receives CMS certification 3️⃣ Celebrating the creation of two new #raredisease centers in the #UK And so much more! 📚 Read all the updates about the cutting-edge technology in #RareLiverDisease that could improve prompt #diagnosis, ongoing feedback, and effective interventions: https://lnkd.in/dcbiTMif #LiverHealth #PatientAdvocacy #liverdisease

18

https://lnkd.in/edPU8C6F Efficient Pd-catalyzed intramolecular O-allylations of ketoximes enable the synthesis of 5-vinyl-2-isoxazolines.

4

https://lnkd.in/eVeQhf63 Iodine promotes an oxidative decarboxylation of α-amino acids, followed by an oxidative cyclization reactio with inexpensive 2-aminobenzamides

7

The #FDA has cleared the IND application for TYRA-300, an oral FGFR3-selective inhibitor, for use in low-grade, intermediate-risk #NMIBC. This regulatory decision paves the way for a phase 2 clinical trial of TYRA-300 in this patient population. #blcsm https://lnkd.in/eDHSH_Zh

7